Freestone Grove Partners LP Buys New Shares in Baxter International Inc. $BAX

Freestone Grove Partners LP bought a new position in Baxter International Inc. (NYSE:BAX) in the second quarter, Holdings Channel.com reports. The firm bought 440,951 shares of the medical instruments supplier’s stock, valued at approximately $9,401,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Basepoint Wealth LLC purchased a new position in shares of Baxter International in the fourth quarter worth about $26,000. Jones Financial Companies Lllp purchased a new stake in Baxter International in the second quarter valued at approximately $26,000. Imprint Wealth LLC purchased a new stake in Baxter International in the third quarter valued at approximately $27,000. MUFG Securities EMEA plc purchased a new position in Baxter International during the 2nd quarter worth approximately $46,000. Finally, Los Angeles Capital Management LLC purchased a new position in Baxter International during the 4th quarter worth approximately $46,000. Institutional investors and hedge funds own 90.19% of the company’s stock.

Wall Street Analysts Forecast Growth

BAX has been the topic of several recent research reports. The Goldman Sachs Group upped their price objective on shares of Baxter International from $19.00 to $21.00 and gave the company a “neutral” rating in a report on Wednesday, July 15th. Stifel Nicolaus raised their target price on shares of Baxter International from $19.00 to $24.00 and gave the stock a “hold” rating in a report on Tuesday, July 28th. TD Cowen boosted their target price on shares of Baxter International from $20.00 to $24.00 and gave the company a “hold” rating in a research report on Monday, July 27th. Citigroup raised shares of Baxter International from a “sell” rating to a “neutral” rating and upped their price target for the company from $17.00 to $28.00 in a report on Friday, July 31st. Finally, Wall Street Zen upgraded Baxter International from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Two analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $22.45.

Baxter International Price Performance

Baxter International stock opened at $25.97 on Friday. The stock has a market capitalization of $13.43 billion, a P/E ratio of -12.55, a P/E/G ratio of 4.01 and a beta of 0.60. The company’s fifty day moving average price is $24.12 and its 200 day moving average price is $20.51. The company has a debt-to-equity ratio of 1.39, a quick ratio of 1.32 and a current ratio of 1.95. Baxter International Inc. has a 1 year low of $15.73 and a 1 year high of $30.00.

Baxter International (NYSE:BAX) last posted its quarterly earnings data on Thursday, July 30th. The medical instruments supplier reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.19. Baxter International had a negative net margin of 9.27% and a positive return on equity of 16.57%. The business had revenue of $2.96 billion for the quarter, compared to the consensus estimate of $2.80 billion. During the same period last year, the firm posted $0.59 earnings per share. The company’s revenue was up 5.3% compared to the same quarter last year. Baxter International has set its FY 2026 guidance at 1.950-2.150 EPS. As a group, equities research analysts anticipate that Baxter International Inc. will post 2.04 earnings per share for the current fiscal year.

Baxter International Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 1st. Investors of record on Friday, August 28th will be paid a $0.01 dividend. The ex-dividend date of this dividend is Friday, August 28th. This represents a $0.04 dividend on an annualized basis and a yield of 0.2%. Baxter International’s dividend payout ratio (DPR) is currently -1.93%.

Baxter International Company Profile

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.